Following the success of previous ESH conferences on AML, it has been decided to organize this translational research conference regularly, as a biennial event.

Molecular techniques are creating novel insights into the biology and therapeutic perspectives of AML. Molecular diagnosis allows us to distinguish distinct disease entities and to identify patients with different disease behavior and prognosis. Genomic and epigenetic studies have revealed entirely novel insights into the biology of AML, expanded the genomic landscape in unprecedented depth and discovered functional clues of dysregulation. Thus, these studies have profoundly enhanced our understanding of the pathobiology of the disease and identified major pathways of malignant transformation. These insights also furnish keys to the development of novel specifically acting therapeutic drugs and provide the opportunity to develop more sophisticated riskadjusted therapeutic approaches.

The program will include:

- Plenary Sessions
- Roundtable Discussions
- Simultaneous Meet the Expert Sessions
- Poster Sessions

Learning Objectives:

Upon completion of this CME activity, participants should be able to:

1. Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.

2. Acquire insight into the possible mechanisms of preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.

3. Understand the characterization of a leukemia stem cell and its relationship to disease development and phenotype.

4. Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia (eg, methylation, microRNA) and its clinical impact.

5. Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.

6. Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, the current developmental status of various targeted drugs and their promises for future clinical application.